• Molecular NameLeuprolide
  • SynonymEligard; Inhalable; leuprolide
  • Weight1209.42
  • Drugbank_IDDB00007
  • ACS_NO53714-56-0
  • Show 2D model
  • LogP (experiment)-0.621
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationImplant / Injection
  • PharmacologyFor treatment of advanced prostate cancer
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding46.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIn healthy male volunteers, a 1 mg bolus of leuprolide administered intravenously revealed that the mean systemic clearance was 8.34 L/h, with a terminal elimination half-life of approximately 3 hours based on a two compartment model.
  • Half life3 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySystemic Adverse Events Reported by >= 2% of Patients Treated with ELIGARD? include malaise, fatigue, dizziness, hot flashes, atrophy of testes, colitis/gastroenteritis.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A